# Vaccine adjuvants

Source: https://onco.cc/terms/vaccine-adjuvants/  
OnCo record `vaccine-adjuvants` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A vaccine adjuvant is an ingredient intended to support an immune response. Its effects depend on the antigen, formulation and exposure; more inflammation does not establish cancer benefit.

## Summary

Vaccine adjuvants support the immune context in which antigen is encountered. Their actions can involve different sensing, recruitment, antigen-availability and activation pathways. Antigen specificity, delivery, useful priming and tumour control remain distinct questions.

The ingredient meaning differs from adjuvant cancer treatment after the main treatment. An adjuvant’s contribution needs a suitable comparison, and immune assay responses, clinical outcomes and harms need separate measurement.

## Fields

- Kind: Term
- Last checked: 2026-11-12
- Also known as: Vaccine adjuvant; Immune adjuvants

## Notes

- A vaccine adjuvant is an ingredient intended to support an immune response to vaccine antigen. In a topic-and-teaching-context analogy, antigen supplies a possible target while the adjuvant changes the context; it does not choose a mature T cell's receptor specificity. Ingredients can affect recruitment, antigen availability, activation and supporting signals through different pathways. An antigen-acquisition diagram with one example sensor and a later priming encounter is simplified: antigen and context have distinct jobs, adjuvants can act on other cells, and a useful response still needs testing.
- Mata-Haro's 2007 experiments studied monophosphoryl lipid A, an LPS-derived TLR4 agonist. In mice, its lower inflammatory toxicity relative to LPS was associated with biased TRIF signalling while retaining adjuvant activity. This is a defined molecule, comparison and model. It does not establish a universal safe amount, route-independent safety or a rule that more innate stimulation improves human cancer outcomes.
- Delivery and adjuvant activity can overlap but answer different questions. Material entering a cell does not establish useful priming, and a lipid carrier's immune effects depend on its composition, payload, route and exposure. Recognition of antigen, entry into tumour tissue, useful function and safety remain separate requirements. Experience with an ingredient in an infection-prevention vaccine does not by itself establish efficacy in cancer treatment.
- Ott's personal melanoma vaccine combined selected long peptides with poly-ICLC, a stabilised synthetic double-stranded RNA immune stimulus. The study's antigen-reactive responses concern that package. There was no randomised estimate of the adjuvant's independent contribution, so the result cannot determine what the same peptides would have done without it or rank every alternative adjuvant.
- Hailemichael's 2013 mouse melanoma experiments found that a persistent short-gp100-peptide depot in incomplete Freund's adjuvant could draw vaccine-reactive T cells to the vaccination site, with dysfunction and deletion. A nonpersisting formulation shifted localisation toward tumours under the tested conditions. The study also found less sequestration and different activity with a longer peptide in the depot formulation. Persistence is therefore not automatically better, but these experiments do not show that every depot adjuvant fails in humans.
- Assess presenting-cell activation, antigen-specific antibody or T-cell responses, persistence and harms with the cell population, units, background controls and sampling time stated. To isolate an adjuvant's contribution, use suitable comparisons with the same antigen and relevant conditions. Changing antigen, carrier and adjuvant together measures a package; it cannot assign the result to one ingredient. Clinical tumour outcomes require separate evidence from an immune assay.
- A vaccine adjuvant is an immune-supporting ingredient, while adjuvant cancer treatment is given after the main treatment. Redness, fever or a high cytokine signal is not proof of useful antigen-specific immunity. A larger measured response may involve different cells, durability and harms, so neither more inflammation nor more stimulation is an automatic success criterion.
- In a fictional comparison, formulations A and B contain the same antigen. A causes more redness; B gives a larger controlled antigen-specific assay response. A has a stronger observed local reaction and B a stronger response under the assay's definition, but neither result establishes cancer control. Check route, sampling, controls, persistence and harms, then the appropriate clinical outcomes, before assigning a benefit to an ingredient.

## Sources

- CDC: adjuvant ingredients and local/systemic reactions: https://www.cdc.gov/vaccine-safety/about/adjuvants.html
- Mata-Haro et al.: MPLA, TLR4 and TRIF-biased signalling in mice (2007): https://pubmed.ncbi.nlm.nih.gov/17569868/
- Caskey et al.: stabilised synthetic double-stranded RNA in human volunteers (2011): https://pubmed.ncbi.nlm.nih.gov/22065672/
- Ott et al.: long peptides with poly-ICLC in melanoma (2017): https://pubmed.ncbi.nlm.nih.gov/28678778/
- Hailemichael et al.: persistent short-peptide depots in mouse melanoma (2013): https://pubmed.ncbi.nlm.nih.gov/23455713/

## Connected records

- terms: [Cancer vaccines and oncolytic viruses](https://onco.cc/terms/vaccines-and-oncolytic-viruses/), [Dendritic-cell cross-presentation (cDC1)](https://onco.cc/terms/dendritic-cell-cross-presentation/), [Intratumoral immunotherapy](https://onco.cc/terms/intratumoral-immunotherapy/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/), [In situ vaccination](https://onco.cc/technologies/in-situ-vaccination/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)

---
JSON: https://onco.cc/api/v1/entities/vaccine-adjuvants.json